Skip to main content
SpringerLink
Log in

Treatment of HCV, HDV, or HIV Coinfections

  • Chapter
  • First Online:
Hepatitis B Virus and Liver Disease

  • 738 Accesses

Abstract

Due to shared routes of infection (parenteral and sexually transmitted), persons with hepatitis B may be infected with other viruses—specifically human immunodeficiency virus, hepatitis D, and hepatitis C. Coinfections lead to an altered natural history of hepatitis B, with higher risk of cirrhosis and liver cancer; thus, screening for coinfections is important in patients with hepatitis B to identify those at heightened risk. Managing patients with coinfections requires longitudinal monitoring of viral co-pathogen activity, awareness of the optimal timing of antiviral therapy for the different coinfections, and attention to the impact of viral interference and viral clearance on clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AIDS:

acquired immunodeficiency syndrome

ALT:

alanine aminotransferase

ART:

antiretroviral therapy

AST:

aspartate aminotransferase

CHB:

chronic hepatitis B

CHD:

chronic hepatitis D

DAA:

direct-acting antiviral

ETV:

entecavir

FTC:

emtricitabine

GFR:

glomerular filtration rate

HBeAg:

hepatitis B e-antigen

HBIG:

hepatitis B immunoglobulin

HBsAg:

hepatitis B surface antigen

HBV:

hepatitis B virus

HCC:

hepatocellular carcinoma

HCV:

hepatitis C virus

HDV:

hepatitis D virus

HIV:

human immunodeficiency virus

LMV:

lamivudine

LT:

liver transplantation

MSM:

men who have sex with men

NA:

nucleos(t)ide analogues

Peg-IFN:

peginterferon

PWIDs:

persons who inject drugs

SVR:

sustained virologic response

TAF:

tenofovir alafenamide

TDF:

tenofovir disoproxil fumarate

References

  • AASLD/IDSA/IAS–USA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Volume 2016; 2016.

    Google Scholar 

  • Abbas Z, Memon M, Mithani H, et al. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther. 2014;19:463–8.

    Article  CAS  PubMed  Google Scholar 

  • Abbas Z, Memon MS, Umer MA, et al. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial. World J Hepatol. 2016;8:625–31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Abbas Z, Saad M, Asim M, et al. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D. Turk J Gastroenterol. 2020;31:136–41.

    Article  PubMed  PubMed Central  Google Scholar 

  • Alberti A, Pontisso P, Fattovich G, et al. Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. J Infect Dis. 1986;154:562–9.

    Article  CAS  PubMed  Google Scholar 

  • Alfaiate D, Clement S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73:533–9.

    Article  PubMed  Google Scholar 

  • Anadol E, Beckebaum S, Radecke K, et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat. 2012;2012:197501.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.

    Article  Google Scholar 

  • Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.

    Article  Google Scholar 

  • Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet. 1987;1:478–80.

    Article  CAS  PubMed  Google Scholar 

  • Audsley J, Avihingsanon A, Littlejohn M, et al. Long-term TDF-inclusive ART and Progressive rates of HBsAg loss in HIV-HBV coinfection-lessons for functional HBV cure? J Acquir Immune Defic Syndr. 2020;84:527–33.

    Article  CAS  PubMed  Google Scholar 

  • Audsley J, Sasadeusz J. Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. Curr Opin HIV AIDS. 2020;15:193–9.

    Article  PubMed  Google Scholar 

  • Babu CK, Suwansrinon K, Bren GD, et al. HIV induces TRAIL sensitivity in hepatocytes. PLoS One. 2009;4:e4623.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran--a systematic review and meta-analysis. PLoS One. 2016;11:e0151946.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bahcecioglu IH, Ispiroglu M, Demirel U, et al. Pegylated interferon alpha therapy in Chronic Delta Hepatitis: a one-center experience. Hepat Mon. 2015;15:e24366.

    Article  PubMed  PubMed Central  Google Scholar 

  • Baig S, Siddiqui AA, Ahmed WU, et al. Frequency of hepatitis C and D super infection in patients with hepatitis B related complex liver disorders. J Coll Physicians Surg Pak. 2009;19:699–703.

    PubMed  Google Scholar 

  • Balagopal A, Hwang HS, Grudda T, et al. Single hepatocyte Hepatitis B virus transcriptional landscape in HIV coinfection. J Infect Dis. 2020;221:1462–9.

    Article  CAS  PubMed  Google Scholar 

  • Baskiran A, Akbulut S, Sahin TT, et al. Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. Hepatol Int. 2020;14:869–80.

    Article  PubMed  Google Scholar 

  • Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2:877–89.

    Article  PubMed  Google Scholar 

  • Beguelin C, Moradpour D, Sahli R, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol. 2017;66:297–303.

    Article  PubMed  Google Scholar 

  • Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27–36.

    Article  CAS  PubMed  Google Scholar 

  • Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–6.

    Article  CAS  PubMed  Google Scholar 

  • Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994;74:2442–8.

    Article  CAS  PubMed  Google Scholar 

  • Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic Hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166:792–8.

    Article  PubMed  Google Scholar 

  • Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51:759–66.

    PubMed  Google Scholar 

  • Bodsworth N, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138–40.

    Article  CAS  PubMed  Google Scholar 

  • Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.

    Article  CAS  PubMed  Google Scholar 

  • Bollinger RC, Thio CL, Sulkowski MS, et al. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV. 2020;7:e443–8.

    Article  PubMed  Google Scholar 

  • Bordier BB, Marion PL, Ohashi K, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol. 2002;76:10465–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17. quiz CE1-4

    PubMed  Google Scholar 

  • Bremer B, Anastasiou OE, Ciesek S, et al. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2019;24:117–23.

    Article  CAS  PubMed  Google Scholar 

  • Brichler S, Le Gal F, Butt A, et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013;11:734–40.

    Article  CAS  PubMed  Google Scholar 

  • Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–90.

    Article  CAS  PubMed  Google Scholar 

  • Bruno R, Sacchi P, Malfitano A, et al. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology. 2001;121:1027–8.

    Article  CAS  PubMed  Google Scholar 

  • Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434–42.

    Article  CAS  PubMed  Google Scholar 

  • Butt ZA, Wong S, Rossi C, et al. Concurrent Hepatitis C and B virus and human immunodeficiency virus infections are associated with higher mortality risk illustrating the impact of Syndemics on health outcomes. Open Forum Infect Dis. 2020a;7:ofaa347.

    Article  PubMed  PubMed Central  Google Scholar 

  • Butt AA, Yan P, Aslam S, et al. Liver fibrosis progression and mortality in Hepatitis B- and C-Coinfected persons treated with directly acting antiviral agents: results from ERCHIVES. Clin Infect Dis. 2020b;71:664–6.

    Article  CAS  PubMed  Google Scholar 

  • Butt AA, Yan P, Shaikh OS, et al. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES. Aliment Pharmacol Ther. 2018;47:412–20.

    Article  CAS  PubMed  Google Scholar 

  • Cabezas C, Trujillo O, Balbuena J, et al. Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B. PLoS One. 2020;15:e0236993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet. 1997;349:995–6.

    Article  CAS  PubMed  Google Scholar 

  • Casey J, Niro G, Engle R, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. 1996;174:920–6.

    Article  CAS  PubMed  Google Scholar 

  • Castelnau C, Le Gal F, Ripault M, et al. Efficacy of peginterferon alfa-2b in chronic delta hepatitis. Relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–35.

    Article  CAS  PubMed  Google Scholar 

  • Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report. J Hepatol. 2011;55:1121–31.

    Article  PubMed  Google Scholar 

  • Chang JJ, Wightman F, Bartholomeusz A, et al. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol. 2005;79:3038–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chemin I, Pujol FH, Scholtes C, et al. Preliminary evidence for hdv exposure in apparently non-HBV-infected patients. Hepatology 2020.

    Google Scholar 

  • Chen X, Oidovsambuu O, Liu P, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected Mongolians. Hepatology. 2017a;66:1739–49.

    Article  CAS  PubMed  Google Scholar 

  • Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017b;66:13–26.

    Article  CAS  PubMed  Google Scholar 

  • Chihota BV, Wandeler G, Chilengi R, et al. High rates of Hepatitis B virus (HBV) functional cure among human immunodeficiency virus-HBV Coinfected patients on antiretroviral therapy in Zambia. J Infect Dis. 2020;221:218–22.

    Article  CAS  PubMed  Google Scholar 

  • Cho LY, Yang JJ, Ko KP, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–84.

    Article  CAS  PubMed  Google Scholar 

  • Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–20.

    Article  PubMed  Google Scholar 

  • Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205:185–93.

    Article  PubMed  Google Scholar 

  • Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cooper C, Driedger M, Wong D, et al. Distinct Hepatitis B and HIV co-infected populations in Canada. J Viral Hepat 2020.

    Google Scholar 

  • Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011;25:777–86.

    Article  PubMed  Google Scholar 

  • Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis Breport from the 2019 EASL-AASLD HBV treatment endpoints conference(double dagger). J Hepatol. 2020;72:539–57.

    Article  CAS  PubMed  Google Scholar 

  • Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2:e35–46.

    Article  PubMed  Google Scholar 

  • De Simone P, Romagnoli R, Tandoi F, et al. Early introduction of subcutaneous Hepatitis B immunoglobulin following liver transplantation for Hepatitis B virus infection: a prospective, multicenter study. Transplantation. 2016;100:1507–12.

    Article  PubMed  CAS  Google Scholar 

  • Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis. 2011;52:257–63.

    Article  CAS  PubMed  Google Scholar 

  • Dezanet LNC, Maylin S, Gabassi A, et al. Kinetics of Hepatitis B Core-related antigen and anti-Hepatitis B Core antibody and their association with serological response in human immunodeficiency virus-Hepatitis B coinfection. J Infect Dis. 2020;221:1826–37.

    Article  CAS  PubMed  Google Scholar 

  • Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis. 2004;39:129–32.

    Article  PubMed  Google Scholar 

  • Dunn D, Price H, Vudriko T, et al. New insights on long-term Hepatitis B virus responses in HIV-Hepatitis B virus co-infected patients: implications for antiretroviral Management in Hepatitis B virus-endemic settings. J Acquir Immune Defic Syndr. 2021;86:98–103.

    Article  CAS  PubMed  Google Scholar 

  • Ehsan H, Wahab A, Shafqat MA, et al. A systematic review of transfusion-transmissible infections among blood donors and associated safety challenges in Pakistan. J Blood Med. 2020;11:405–20.

    Article  PubMed  PubMed Central  Google Scholar 

  • El Bouzidi K, Elamin W, Kranzer K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33–7.

    Article  PubMed  Google Scholar 

  • Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–10.

    Article  CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.

    Article  Google Scholar 

  • European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017a;67:370–98.

    Article  Google Scholar 

  • European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.

    Article  Google Scholar 

  • European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017b.

    Google Scholar 

  • Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health. 2011;8:512–20.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fang L, Yu A, Buxton JA. Identification of chronic hepatitis B and hepatitis C co-infection in British Columbia from 1991 to 2007. Can J Public Health. 2009;100:349–52.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. the European concerted action on viral Hepatitis (Eurohep). Gut. 2000;46:420–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fong TL, Lee BT, Chang M, et al. High prevalence of chronic viral Hepatitis and liver fibrosis among Mongols in Southern California. Dig Dis Sci. 2020;

    Google Scholar 

  • Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol. 2011;55:507–9.

    Article  PubMed  Google Scholar 

  • Franchello A, Ghisetti V, Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl. 2005;11:922–8.

    Article  PubMed  Google Scholar 

  • Fung J, Wong T, Chok K, et al. Long term outcomes of Entecavir monotherapy for chronic Hepatitis B after liver transplantation: results up to 8 years. Hepatology 2017.

    Google Scholar 

  • Gallant J, Brunetta J, Crofoot G, et al. Brief report: efficacy and safety of switching to a single-tablet regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected adults. J Acquir Immune Defic Syndr. 2016;73:294–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gheorghe L, Iacob S, Simionov I, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011;20:377–82.

    PubMed  Google Scholar 

  • Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991;163:454–9.

    Article  CAS  PubMed  Google Scholar 

  • Hafkin JS, Osborn MK, Localio AR, et al. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat. 2014;21:288–96.

    Article  CAS  PubMed  Google Scholar 

  • Hamid S, Etzion O, Lurie Y, et al. A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV study (abstr.). Hepatology. 2017;66:496A.

    Google Scholar 

  • Hartl J, Ott C, Kirchner G, et al. Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin. Clin Pract. 2012;2:e64.

    Article  PubMed  PubMed Central  Google Scholar 

  • Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.

    Article  CAS  PubMed  Google Scholar 

  • Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Herrscher C, Roingeard P, Blanchard E, Hepatitis B. Virus entry into cells. Cell. 2020;9:1486.

    Article  CAS  Google Scholar 

  • http://replicor.com/pipeline/. Accessed January 3, 2021.

    Google Scholar 

  • https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex#product-information-section (n.d.).

  • Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.

    Article  PubMed  Google Scholar 

  • Hung CC, Wu SM, Lin PH, et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis. 2014;58:1625–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iser DM, Warner N, Revill PA, et al. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol. 2010;84:5860–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34:404–10.

    Article  CAS  PubMed  Google Scholar 

  • Jaroszewicz J, Reiberger T, Meyer-Olson D, et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One. 2012;7:e43143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang XW, Ye JZ, Li YT, et al. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: a systematic review and meta-analysis. World J Gastroenterol. 2018;24:3181–91.

    Article  PubMed  PubMed Central  Google Scholar 

  • Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.

    Article  PubMed  Google Scholar 

  • Kamal H, Westman G, Falconer K, et al. Long-term study of Hepatitis Delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020;72:1177–90.

    Article  PubMed  Google Scholar 

  • Kang C, Syed YY. Bulevirtide: First Approval. Drugs. 2020;80:1601–5.

    Article  CAS  PubMed  Google Scholar 

  • Keskin O, Wedemeyer H, Tuzun A, et al. Association between level of Hepatitis D virus RNA at week 24 of Pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol. 2015;13:2342–49 e1-2.

    Article  CAS  PubMed  Google Scholar 

  • Khalili M, King WC, Kleiner DE, et al. Fatty liver disease in a prospective north American cohort of adults with HIV and Hepatitis B coinfection. Clin Infect Dis 2020.

    Google Scholar 

  • Kim YJ, Lee JW, Kim YS, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol. 2011;17:199–205.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim HN, Nance R, Van Rompaey S, et al. Poorly controlled HIV infection: an independent risk factor for liver fibrosis. J Acquir Immune Defic Syndr. 2016;72:437–43.

    Article  PubMed  Google Scholar 

  • Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral Hepatitis Coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160–7.

    PubMed  PubMed Central  Google Scholar 

  • Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586–92.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169–79.

    Article  CAS  PubMed  Google Scholar 

  • Le Gal F, Brichler S, Sahli R, et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64:1483–94.

    Article  PubMed  CAS  Google Scholar 

  • Le Gal F, Dziri S, Gerber A, et al. Performance characteristics of a new consensus commercial kit for Hepatitis D virus RNA viral load quantification. J Clin Microbiol. 2017;55:431–41.

    Article  PubMed  PubMed Central  Google Scholar 

  • Liaw Y. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101–8.

    CAS  PubMed  Google Scholar 

  • Liaw Y, Chen Y, Sheen I, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024–9.

    Article  PubMed  Google Scholar 

  • Lin HH, Lee SS, Yu ML, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015;61:1870–9.

    Article  CAS  PubMed  Google Scholar 

  • Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–36.

    Article  PubMed  Google Scholar 

  • Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with Hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.

    Article  CAS  PubMed  Google Scholar 

  • Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of Ledipasvir and Sofosbuvir treatment of HCV infection in patients Coinfected with HBV. Gastroenterology. 2018;154:989–97.

    Article  CAS  PubMed  Google Scholar 

  • Lu SN, Chen TM, Lee CM, et al. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J Med Virol. 2003;70:74–80.

    Article  CAS  PubMed  Google Scholar 

  • Mahale P, Aka P, Chen X, et al. Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in the Gambia. J Viral Hepat. 2019;26:738–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Makuza JD, Nisingizwe MP, Rwema JOT, et al. Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study. BMJ Open. 2020;10:e036711.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;31(Suppl 1):135–9.

    Article  PubMed  Google Scholar 

  • Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.

    Article  CAS  PubMed  Google Scholar 

  • Maylin S, Boyd A, Lavocat F, et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS. 2012;26:939–49.

    Article  CAS  PubMed  Google Scholar 

  • McKee G, Butt ZA, Wong S, et al. Syndemic characterization of HCV, HBV, and HIV co-infections in a large population based cohort study. E Clin Med. 2018;4-5:99–108.

    Google Scholar 

  • Mentha N, Clement S, Negro F, et al. A review on hepatitis D: from virology to new therapies. J Adv Res. 2019;17:3–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Merchante N, Figueruela B, Rodriguez-Fernandez M, et al. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 2019b;33:269–78.

    Article  PubMed  Google Scholar 

  • Merchante N, Saroli Palumbo C, Mazzola G, et al. Prediction of esophageal varices by liver stiffness and platelets in persons with HIV infection and compensated advanced chronic liver disease. Clin Infect Dis 2019a.

    Google Scholar 

  • Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9.

    Article  CAS  PubMed  Google Scholar 

  • Moorman AC, Xing J, Rupp LB, et al. Hepatitis B virus infection and Hepatitis C virus treatment in a large cohort of Hepatitis C-infected patients in the United States. Gastroenterology. 2018;154:754–8.

    Article  PubMed  Google Scholar 

  • Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:172–80.

    Article  PubMed  Google Scholar 

  • Mumtaz K, Ahmed US, Memon S, et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 2011;8:312.

    Article  PubMed  PubMed Central  Google Scholar 

  • Neukam K, Mira JA, Collado A, et al. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral Hepatitis in a real-life setting: the HEPAVIR SEG-HEP cohort. PLoS One. 2016;11:e0148104.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Nguyen LH, Ko S, Wong SS, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011;53:1839–45.

    Article  PubMed  Google Scholar 

  • Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–71.

    Article  PubMed  Google Scholar 

  • Niro G, Ciancio A, Gaeta G, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–20.

    Article  CAS  PubMed  Google Scholar 

  • Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.

    Article  CAS  PubMed  Google Scholar 

  • Palom A, Rodriguez-Tajes S, Navascues CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Aliment Pharmacol Ther. 2020;51:158–66.

    Article  CAS  PubMed  Google Scholar 

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. In: Services DoHaH, ed. Volume 2020.

    Google Scholar 

  • Papadopoulos N, Papavdi M, Pavlidou A, et al. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. Ann Gastroenterol. 2018;31:365–70.

    PubMed  PubMed Central  Google Scholar 

  • Perez-Vargas J, Amirache F, Boson B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat Commun. 2019;10:2098.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pfluger LS, Schulze Zur Wiesch J, Polywka S, et al. Hepatitis delta virus propagation enabled by hepatitis C virus-scientifically intriguing, but is it relevant to clinical practice? J Viral Hepat. 2021;28:213–6.

    Article  PubMed  CAS  Google Scholar 

  • Platt L, French CE, McGowan CR, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27:294–315.

    Article  PubMed  Google Scholar 

  • Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008a;49:688–94.

    Article  CAS  PubMed  Google Scholar 

  • Potthoff A, Wedemeyer H, Boecher W, et al. The Hep-net B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-a2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008b;48:S320.

    Article  Google Scholar 

  • Puigvehi M, Moctezuma-Velazquez C, Villanueva A, et al. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep. 2019;1:120–30.

    Article  PubMed  PubMed Central  Google Scholar 

  • Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–7.

    Article  PubMed  Google Scholar 

  • Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2007;44:557–61.

    Article  PubMed  Google Scholar 

  • Ranin J, Salemovic D, Brmbolic B, et al. Comparison of demographic, epidemiological, immunological, and clinical characteristics of patients with HIV mono-infection versus patients co-infected with HCV or/and HBV: a Serbian cohort study. Curr HIV Res. 2018;16:222–30.

    Article  CAS  PubMed  Google Scholar 

  • Roche B, Roque-Afonso AM, Nevens F, et al. Rational basis for optimizing short and long-term Hepatitis B virus prophylaxis post liver transplantation: role of Hepatitis B immune globulin. Transplantation. 2015;99:1321–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–16.

    Article  CAS  PubMed  Google Scholar 

  • Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of Hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–38.

    Article  PubMed  Google Scholar 

  • Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol. 2020;73:1046–62.

    Article  CAS  PubMed  Google Scholar 

  • Safaie P, Razeghi S, Rouster SD, et al. Hepatitis D diagnostics:utilization and testing in the United States. Virus Res. 2018;250:114–7.

    Article  CAS  PubMed  Google Scholar 

  • Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.

    Article  CAS  PubMed  Google Scholar 

  • Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

    Article  CAS  PubMed  Google Scholar 

  • Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–8.

    Article  CAS  PubMed  Google Scholar 

  • Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–64.

    Article  CAS  PubMed  Google Scholar 

  • Shattock AG, Morris M, Kinane K, et al. The serology of delta hepatitis and the detection of IgM anti-HD by EIA using serum derived delta antigen. J Virol Methods. 1989;23:233–40.

    Article  CAS  PubMed  Google Scholar 

  • Shekhtman L, Cotler SJ, Hershkovich L, et al. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep. 2020;10:7837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–7.

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat. 2011;18:449–57.

    Article  CAS  PubMed  Google Scholar 

  • Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS. 2008;22:1399–410.

    Article  PubMed  Google Scholar 

  • Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e364–72.

    Article  PubMed  Google Scholar 

  • Sterling RK, King WC, Wahed AS, et al. Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV co-infected adults. Hepatology. 2020;71:411–21.

    Article  CAS  PubMed  Google Scholar 

  • Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.

    Article  CAS  PubMed  Google Scholar 

  • Sterling RK, Wahed AS, King WC, et al. Spectrum of liver disease in Hepatitis B virus (HBV) patients co-infected with human immunodeficiency virus (HIV): results of the HBV-HIV cohort study. Am J Gastroenterol. 2019;114:746–57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Stockdale AJ, Chaponda M, Beloukas A, et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e992–e1003.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020a;73:523–32.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020b.

    Google Scholar 

  • Stroffolini T, Ciancio A, Furlan C, et al. Migratory flow and hepatitis delta infection in Italy: a new challenge at the beginning of the third millennium. J Viral Hepat. 2020;27:941–7.

    Article  CAS  PubMed  Google Scholar 

  • Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS. 2009;23:1069–76.

    Article  PubMed  Google Scholar 

  • Terrault NA, Berenguer M, Strasser SI, et al. International liver transplantation society consensus statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017;101:956–67.

    Article  PubMed  Google Scholar 

  • Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

    Article  PubMed  Google Scholar 

  • Terrault NA, Ghany MG. Enhanced screening for Hepatitis D in the USA: overcoming the Delta blues. Dig Dis Sci 2020.

    Google Scholar 

  • Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018a;67:1560–99.

    Article  PubMed  Google Scholar 

  • Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment and of chronic Hepatitis B: AASLD 2018 Hepatitis B guidance. Hepatology. 2018b;67:1560–99.

    Article  PubMed  Google Scholar 

  • Thibault V, Stitou H, Desire N, et al. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther. 2011;16:199–205.

    Article  CAS  PubMed  Google Scholar 

  • Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138–45.

    Article  PubMed  Google Scholar 

  • Thio C, Seaberg E, Skolasky RJ, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet. 2002;360:1921–6.

    Article  PubMed  Google Scholar 

  • Thornton AC, Jose S, Bhagani S, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017;31:2525–32.

    Article  PubMed  Google Scholar 

  • Tsai WC, Hsu WT, Liu WD, et al. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. Liver Int. 2019;39:1408–17.

    Google Scholar 

  • Tsatsralt-Od B, Takahashi M, Nishizawa T, et al. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77:491–9.

    Article  CAS  PubMed  Google Scholar 

  • Tyson GL, Kramer JR, Duan Z, et al. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58:538–45.

    Article  PubMed  Google Scholar 

  • Uyanikoglu A, Akyuz F, Baran B, et al. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2013;37:485–90.

    Article  PubMed  Google Scholar 

  • Wandeler G, Gsponer T, Bihl F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013;208:1454–8.

    Article  CAS  PubMed  Google Scholar 

  • Wandeler G, Mauron E, Atkinson A, et al. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: relevance for screening strategies. J Hepatol. 2019;71:274–80.

    Article  CAS  PubMed  Google Scholar 

  • Wang Q, De Luca A, Smith C, et al. Chronic Hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study. Ann Intern Med. 2017;166:9–17.

    Article  PubMed  Google Scholar 

  • Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology. 2007;45:1331–2. Author reply 1332-3

    Article  PubMed  Google Scholar 

  • Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.

    Article  CAS  PubMed  Google Scholar 

  • Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2011;31:755–61.

    Article  PubMed  Google Scholar 

  • Willemse S, Smit C, Sogni P, et al. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. J Viral Hepat. 2019;26:1224–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wranke A, Hardtke S, Heidrich B, et al. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. J Viral Hepat. 2020;27:1359–68.

    Article  CAS  PubMed  Google Scholar 

  • Wranke A, Heidrich B, Ernst S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014;9:e101002.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wranke A, Serrano BC, Heidrich B, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65:414–25.

    Article  CAS  PubMed  Google Scholar 

  • Yang WT, Wu LW, Tseng TC, et al. Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual Hepatitis B and C infection. Medicine (Baltimore). 2016;95:e2995.

    Article  CAS  Google Scholar 

  • Yeh ML, Huang CF, Huang CI, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020;73:62–71.

    Article  CAS  PubMed  Google Scholar 

  • Yu S, Yu C, Li J, et al. Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and meta-analysis. Virol J. 2020;17:127.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–21.

    Article  CAS  PubMed  Google Scholar 

  • Yurdaydin C, Kalkan C, Karakaya F, et al. Sub-analysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads. J Hepatol. 2018a;68:S898.

    Article  Google Scholar 

  • Yurdaydin C, Keskin O, Kalkan C, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018b;67:1224–36.

    Article  CAS  PubMed  Google Scholar 

  • Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14:75–82.

    Article  CAS  PubMed  Google Scholar 

  • Zhang Q, Qi W, Wang X, et al. Epidemiology of Hepatitis B and Hepatitis C infections and benefits of programs for Hepatitis prevention in northeastern China: a cross-sectional study. Clin Infect Dis. 2016;62:305–12.

    Article  PubMed  Google Scholar 

  • Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province. China PLoS One. 2012;7:e42937.

    Article  CAS  PubMed  Google Scholar 

  • Zignego AL, Samuel D, Gigou M, et al. Patterns of hepatitis delta reinfection after liver transplantation and their evolution during a long term follow-up. Prog Clin Biol Res. 1993;382:409–17.

    CAS  PubMed  Google Scholar 

  • Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al. Hepatitis B surface antigen declines and clearance during long-term Tenofovir therapy in patients Coinfected with HBV and HIV. J Infect Dis. 2012;206:974–80.

    Article  CAS  PubMed  Google Scholar 

  • Zuberi BF, Afsar S, Quraishy MS. Triple hepatitis: frequency and treatment outcome of co/super-infection of hepatitis C and D among patients of hepatitis B. J Coll Physicians Surg Pak. 2008;18:404–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, USA

    Kali Zhou & Norah A. Terrault

Authors
  1. Kali Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norah A. Terrault
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norah A. Terrault .

Editor information

Editors and Affiliations

  1. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

    Jia-Horng Kao

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhou, K., Terrault, N.A. (2021). Treatment of HCV, HDV, or HIV Coinfections. In: Kao, JH. (eds) Hepatitis B Virus and Liver Disease. Springer, Singapore. https://doi.org/10.1007/978-981-16-3615-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-3615-8_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-3614-1

  • Online ISBN: 978-981-16-3615-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation